University of Iowa Health Care
Iowa City, Iowa, 52240, United States
Location status: Recruiting
NCT Number: NCT06405607
This study will collect data that measures the effects of a psychedelic intervention on patients struggling with alcohol use disorder (AUD). The study design will be a double blind, randomized, active-comparator trial with two study arms. Subjects randomized to Arm 1 (n=40) will receive individual psychotherapy sessions plus a 30 mg dose of psilocybin. Arm 2 subjects (n=40) will receive individual psychotherapy sessions and a 0.75 mg/kg dose of ketamine.
Interested in participating?
Request Info21 year–65 year
All sexes
Interventional
Phase 2
Iowa City, Iowa, 52240, United States
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Drug/medication assessment that yields: nonprescription medication use, nutritional supplement, or herbal supplement (except when approved by the study investigators), medically unstable, current medication use that has significant potential to interact with study drug (e.g., antidepressants, antipsychotics, psychostimulants, treatments for addictions, other dopaminergic or serotonergic agents, lithium, anticonvulsants, or benzodiazepines).
Psychiatric assessment that yields:1) history of severe suicide attempt, 2) current suicidality 3) first-degree relative with schizophrenia or schizoaffective disorder, 4) comorbid substance use disorder including cocaine, psychostimulant, or opioid use disorder within past 12 months 5) history of co-occurring psychotic episode/diagnosis including schizophrenia, schizoaffective disorder, schizophreniform, substance-induced psychosis, delusional disorder, or psychosis not otherwise specified, 6) high risk of adverse emotional or behavioral reaction based on the medical monitor's clinical evaluation that may also yield evidence of serious current stressors, a lack of meaningful social support, antisocial behavior, and/or serious personality disorders amongst other conditions.
Medical assessment that yields: serious ECG abnormalities (evidence of ischemia, myocardial infarction, QTc prolongation [QTc > .045]), serious abnormalities of complete blood count or chemistries, medical conditions that would preclude safe participation (significantly impaired liver function), or pregnancy.
MRI contraindication (pacemaker, etc.)
30 mg single dose
0.75 mg/kg weight-based single dose
Time frame: Weekly, over the course of 16 weeks
Quantifies daily alcohol use
Time frame: Twice (before intervention, post intervention): at week 1 and week 16
Measures biological changes in the brain
Time frame: Twice (before intervention, post intervention):: at week 1 and week 16
Measures biological changes in brain resting state global functional connectivity
Time frame: Twice (before drug administration and at peak of drug experience) during week 3
Measures electrical signal change
Contact information is provided by the study sponsor or research team.
Lindsay E Golden, BS
CONTACT
Peggy C Nopoulos, MD
CONTACT
University of Iowa
Other
Psilocybin vs Ketamine for Alcohol Use Disorder
Acronym: Psi or Ket
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07216872
Alcohol Abuse, Alcohol Abuse/Dependence
Tuscaloosa, Alabama, United States
View Trial DetailsNCT06265506
Alcohol Abstinence, Alcohol Abuse
Spokane, Washington, United States
View Trial DetailsNCT04154111
Alcohol Abuse, Alcohol Dependence
Winston-Salem, North Carolina, United States
View Trial DetailsNCT03952429
Alcohol Abuse, Alcohol Dependence
Lindow, Brandenburg, Germany
View Trial Details